1
|
Andrade I, Ribeiro R, Carneiro ZA, Giugliani R, Pereira C, Cozma C, Grinberg D, Vilageliu L, Lourenco CM. Fifteen years of enzyme replacement therapy for mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome): a case report. J Med Case Rep 2022; 16:46. [PMID: 35078524 PMCID: PMC8787900 DOI: 10.1186/s13256-021-03240-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2020] [Accepted: 12/22/2021] [Indexed: 11/23/2022] Open
Abstract
Background Mucopolysaccharidosis VI, or Maroteaux–Lamy disease, is an autosomal recessive disease characterized by deficiency of the enzyme arylsulfatase B in the lysosomal catabolism of glycosaminoglycans. Due to reduced (or even null) enzyme activity, glycosaminoglycans (mainly dermatan sulfate) accumulates, leading to a multisystemic disease. Mucopolysaccharidosis VI induces reduced growth, coarse face, audiovisual deficits, osteoarticular deformities, and cardiorespiratory issues, hampering the quality of life of the patient. Enzyme replacement therapy with galsulfase (Naglazyme, BioMarin Pharmaceuticals Inc., USA) is the specific treatment for this condition. Although studies have shown that enzyme replacement therapy slows the progression of the disease, the effects of long-term enzyme replacement therapy remain poorly understood. Case presentation A 29-year-old, Caucasian, male patient diagnosed with mucopolysaccharidosis VI was treated with enzyme replacement therapy for over 15 years. Enzyme replacement therapy was initiated when patient was 13 years old. The patient evolved multiplex dysostosis, carpal tunnel syndrome, thickened mitral valve, and hearing and visual loss.
Conclusions Although enzyme replacement therapy did not prevent the main signs of mucopolysaccharidosis VI, it slowed their progression. Additionally, enzyme replacement therapy was associated with a longer survival compared with the untreated affected sibling. Taken together, the results indicate that enzyme replacement therapy positively modified the course of the disease.
Collapse
Affiliation(s)
- Isadora Andrade
- Faculdade de Medicina, Centro Universitário Estácio de Ribeirão Preto, Rua Abrahão Issa Halach, 980, Ribeirânia, Ribeirão Preto, SP, 14096-160, Brazil
| | - River Ribeiro
- Faculdade de Medicina, Centro Universitário Estácio de Ribeirão Preto, Rua Abrahão Issa Halach, 980, Ribeirânia, Ribeirão Preto, SP, 14096-160, Brazil
| | - Zumira A Carneiro
- Faculdade de Medicina, Centro Universitário Estácio de Ribeirão Preto, Rua Abrahão Issa Halach, 980, Ribeirânia, Ribeirão Preto, SP, 14096-160, Brazil
| | - Roberto Giugliani
- Serviço de Genética Médica e Grupo de Pesquisa DR BRASIL, Hospital das Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.,Departamento de Genética, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
| | | | | | - Daniel Grinberg
- Departament de Genètica, Microbiologia i Estadística, Facultat de Biologia, Universitat de Barcelona, CIBERER, IBUB, IRSJD, Barcelona, Spain
| | - Lluïsa Vilageliu
- Departament de Genètica, Microbiologia i Estadística, Facultat de Biologia, Universitat de Barcelona, CIBERER, IBUB, IRSJD, Barcelona, Spain
| | - Charles M Lourenco
- Faculdade de Medicina, Centro Universitário Estácio de Ribeirão Preto, Rua Abrahão Issa Halach, 980, Ribeirânia, Ribeirão Preto, SP, 14096-160, Brazil.
| |
Collapse
|
2
|
Lourenço CM, Dovidio J, Lopes IF, Silva LC, Almeida M, Vagnini L, Fonseca J, Carneiro ZA, Thöny B. Sapropterin dihydrochloride therapy in dihydropteridine reductase deficiency: Insight from the first case with molecular diagnosis in Brazil. JIMD Rep 2021; 61:19-24. [PMID: 34485013 PMCID: PMC8411105 DOI: 10.1002/jmd2.12224] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/03/2020] [Revised: 04/03/2021] [Accepted: 04/19/2021] [Indexed: 11/08/2022] Open
Abstract
Tetrahydrobiopterin (BH4) is a cofactor that participates in the biogenesis reactions of a variety of biomolecules, including l-tyrosine, l-3,4-dihydroxyphenylalanine, 5-hydroxytryptophan, nitric oxide, and glycerol. Dihydropteridine reductase (DHPR, EC 1.5.1.34) is an enzyme involved in the BH4 regeneration. DHPR deficiency (DHPRD) is an autosomal recessive disorder, leading to severe and progressive neurological manifestations, which cannot be exclusively controlled by l-phenylalanine (l-Phe) restricted diet. In fact, the supplementation of neurotransmitter precursors is more decisive in the disease management, and the administration of sapropterin dihydrochloride may also provide positive effects. From the best of our knowledge, there is limited information regarding DHPRD in the past 5 years in the literature. Here, we describe the medical journey of the first patient to have DHPRD confirmed by molecular diagnostic methods in Brazil. The patient presented with two pathogenic variants of the quinoid dihydropteridine reductase (QDPR) gene-which codes for the DHPR protein, one containing the in trans missense mutation c.515C>T (pPro172Leu) in exon 5 and the other containing the same type of mutation in the exon 7 (c.635T>C [p.Phe212Ser]). The authors discuss their experience with sapropterin dihydrochloride for the treatment of DHPRD in this case report.
Collapse
Affiliation(s)
| | - Janaina Dovidio
- Centro Universitário Estácio de Ribeirão PretoSão PauloBrazil
| | | | - Laís C. Silva
- Centro Universitário Estácio de Ribeirão PretoSão PauloBrazil
| | - Marcela Almeida
- Centro Universitário Estácio de Ribeirão PretoSão PauloBrazil
| | - Laura Vagnini
- Centro Paulista de Diagnóstico e Pesquisa em Genética ClínicaSão PauloBrazil
| | | | | | - Beat Thöny
- Division of MetabolismUniversity Children's HospitalZürichSwitzerland
| |
Collapse
|
3
|
Gaspari APS, da Silva RS, Carneiro ZA, de Carvalho MR, Carvalho I, Pernomian L, Ferreira LP, Ramos LCB, de Souza GA, Formiga ALB. Improving Cytotoxicity against Breast Cancer Cells by Using Mixed-Ligand Ruthenium(II) Complexes of 2,2'-Bipyridine, Amino Acid, and Nitric Oxide Derivatives as Potential Anticancer Agents. Anticancer Agents Med Chem 2021; 21:1602-1611. [PMID: 33081686 DOI: 10.2174/0929867327666201020155105] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2020] [Revised: 08/31/2020] [Accepted: 09/06/2020] [Indexed: 11/22/2022]
Abstract
BACKGROUND Several metal-based molecules that display cytotoxicity against multiple cell lines have been pursued in an attempt to fight against cancer and to overcome the typical side effects of drugs like cisplatin. In this scenario, ruthenium complexes have been extensively studied due to their activity in both in vitro and in vivo biological systems, including various cancer cell strains. OBJECTIVE We aimed to develop a method to synthesize novel [Ru(NO)(bpy)2L2]2+ complexes containing amino acid ligands by using an alternative Click Chemistry approach, namely the copper azide-alkyne cycloaddition reaction (CuAAC reaction), to construct nitrosyl/nitrite complexes bearing a modified lysine residue. METHODS We synthesized a new ligand by Click Chemistry approach and new compounds bearing the unprecedented ligand. Cytotoxicity was assessed by the classical MTT colorimetric assay. MCF-7 and MDAMB- 231 cells were used as breast cancer cell models. MCF-10 was used as a model of healthy cells. RESULTS Amino acid ligands related to N3-Lys(Fmoc) and the new pyLys were successfully synthesized by the diazotransfer reaction and the CuAAC reaction, respectively. The latter reaction involves coupling between N3-Lys(Fmoc) and 3ethynylpyridine. Both N3-Lys(Fmoc) and the new pyLys were introduced into the ruthenium bipyridine complex I, or cis-[RuII(NO)(NO2)(bpy)2]2+, to generate the common nitro-based complex III, which was further converted to the final complex IV. Results of the MTT assay proved the cytotoxic effect of cis- [RuII(NO)(pyLysO-)(bpy)2](PF6)2 against the mammalian breast cancer cells MCF-7 and MDA-MB231. CONCLUSION The viability assays revealed that complex IV, bearing a NO group and a modified lysine residue, was able to release NO and cross tumor cell membranes. In this work, Complex IV was observed to be the most active ruthenium bipyridine complex against the mammalian breast cancer cells MCF-7 and MDA-MB231: it was approximately twice as active as cisplatin, whilst complexes I-III proved to be less cytotoxic than complex IV. Additional tests using healthy MCF 10A cells showed that complexes II-IV were three- to sixfold less toxic than cisplatin, which suggested that complex IV was selective against cancer cells.
Collapse
Affiliation(s)
- Ana P S Gaspari
- Instituto Federal do Parana (IFPR), Avenida Jose Felipe Tequinha, 1400, Paranavaí/PR, 87703-536, Brazil
| | - Roberto Santana da Silva
- School of Pharmaceutical Sciences of Ribeirao Preto, Universidade de Sao Paulo, Avenida do Cafe, s/n, Ribeirao Preto/SP, 14040- 903, Brazil
| | - Zumira A Carneiro
- School of Pharmaceutical Sciences of Ribeirao Preto, Universidade de Sao Paulo, Avenida do Cafe, s/n, Ribeirao Preto/SP, 14040- 903, Brazil
| | - Marcelo Rodrigues de Carvalho
- School of Pharmaceutical Sciences of Ribeirao Preto, Universidade de Sao Paulo, Avenida do Cafe, s/n, Ribeirao Preto/SP, 14040- 903, Brazil
| | - Ivone Carvalho
- School of Pharmaceutical Sciences of Ribeirao Preto, Universidade de Sao Paulo, Avenida do Cafe, s/n, Ribeirao Preto/SP, 14040- 903, Brazil
| | - Laena Pernomian
- School of Pharmaceutical Sciences of Ribeirao Preto, Universidade de Sao Paulo, Avenida do Cafe, s/n, Ribeirao Preto/SP, 14040- 903, Brazil
| | - Lucimara P Ferreira
- Universidade Estadual de Minas Gerais (UEMG), Avenida Prof. Mário Palmerio, 1001, Frutal/MG, 38200-000, Brazil
| | - Loyanne C B Ramos
- School of Pharmaceutical Sciences of Ribeirao Preto, Universidade de Sao Paulo, Avenida do Cafe, s/n, Ribeirao Preto/SP, 14040- 903, Brazil
| | - Gabriel Aguiar de Souza
- Instituto de Quimica, Universidade Estadual de Campinas (UNICAMP), Campinas/SP, 13083-970, Brazil
| | - André L B Formiga
- Instituto de Quimica, Universidade Estadual de Campinas (UNICAMP), Campinas/SP, 13083-970, Brazil
| |
Collapse
|
4
|
Sousa LM, Souza WA, Paixão DA, Fazzi RB, Tezuka DY, Lopes CD, Carneiro ZA, Moreira MB, Pivatto M, Netto AV, de Albuquerque S, Ferreira FB, De Oliveira RJ, Resende JA, Lino RC, De Oliveira Júnior RJ, Da Costa Ferreira AM, Guerra W. DNA binding, cleavage, apoptosis and cytotoxicity studies of three heteroleptic nickel complexes bearing β-diketones. Inorganica Chim Acta 2020. [DOI: 10.1016/j.ica.2020.119824] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
|
5
|
Paixão DA, de Oliveira BC, Almeida JDC, Sousa LM, Lopes CD, Carneiro ZA, Tezuka DY, Clavijo JCT, Ellena J, Polloni L, Machado PH, de Albuquerque S, de Oliveira Júnior RJ, Guilardi S, Guerra W. Crystal structure, anti-Trypanosoma cruzi and cytotoxic activities of Cu(II) complexes bearing β-diketone and α-diimine ligands. Inorganica Chim Acta 2020. [DOI: 10.1016/j.ica.2019.119164] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
|
6
|
Lopes CD, Possato B, Gaspari APS, Oliveira RJ, Abram U, Almeida JPA, Rocho FDR, Leitão A, Montanari CA, Maia PIS, da Silva JS, de Albuquerque S, Carneiro ZA. Organometallic Gold(III) Complex [Au(Hdamp)(L1 4)] + (L1 = SNS-Donating Thiosemicarbazone) as a Candidate to New Formulations against Chagas Disease. ACS Infect Dis 2019; 5:1698-1707. [PMID: 31419384 DOI: 10.1021/acsinfecdis.8b00284] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Chagas disease remains a serious public health concern with unsatisfactory treatment outcomes due to strain-specific drug resistance and various side effects. To identify new therapeutic drugs against Trypanosoma cruzi, we evaluated both the in vitro and in vivo activity of the organometallic gold(III) complex [Au(III)(Hdamp)(L14)]Cl (L1 = SNS-donating thiosemicarbazone), henceforth denoted 4-Cl. Our results demonstrated that 4-Cl was more effective than benznidazole (Bz) in eliminating both the extracellular trypomastigote and intracellular amastigote forms of the parasite without cytotoxic effects on mammalian cells. In in vivo assays, 4-Cl in PBS solution loses the protonation and becomes the 4-neutral. 4-Neutral reduced parasitaemia and tissue parasitism in addition to protecting the liver and heart from tissue damage at 2.8 mg/kg/day. All these changes resulted in the survival of 100% of the mice treated with the gold complex during the acute phase. Analyzing the surviving animals of the acute infection, the parasite load after 150 days of infection was equivalent to those treated with the standard dose of Bz without demonstrating the hepatotoxicity of the latter. In addition, we identified a modulation of interferon gamma (IFN-γ) levels that may be targeting the disease's positive outcome. To the best of our knowledge, this is the first gold organometallic study that shows promise in an in vivo experimental model against Chagas disease.
Collapse
Affiliation(s)
- Carla Duque Lopes
- Department of Clinical Toxicological and Bromatological Analysis School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo (USP), Ribeirão Preto, São Paulo 14040-903, Brazil
- Departament of Biochemistry and Immunology, School of Medicine, University of São Paulo, Ribeirão Preto, São Paulo 14049-900, Brazil
| | - Bruna Possato
- Department of Clinical Toxicological and Bromatological Analysis School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo (USP), Ribeirão Preto, São Paulo 14040-903, Brazil
| | - Ana Paula S. Gaspari
- Department of Clinical Toxicological and Bromatological Analysis School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo (USP), Ribeirão Preto, São Paulo 14040-903, Brazil
| | - Ronaldo J. Oliveira
- Núcleo de Desenvolvimento de Compostos Bioativos (NDCBio), Universidade Federal do Triângulo Mineiro, Uberaba, Minas Gerais 38025-470, Brazil
| | - Ulrich Abram
- Institute of Chemistry and Biochemistry, Freie Universität Berlin, Berlin D-14195, Germany
| | - José P. A. Almeida
- Department of Clinical Toxicological and Bromatological Analysis School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo (USP), Ribeirão Preto, São Paulo 14040-903, Brazil
| | - Fernanda dos Reis Rocho
- Grupo de Estudos em Química Medicinal de Produtos Naturais−NEQUIMED-PN, Instituto de Química de São Carlos, Universidade de São Paulo, Av. Trabalhador Sancarlense 400, P.O. Box 780, São Carlos, São Paulo 13560-960, Brazil
| | - Andrei Leitão
- Grupo de Estudos em Química Medicinal de Produtos Naturais−NEQUIMED-PN, Instituto de Química de São Carlos, Universidade de São Paulo, Av. Trabalhador Sancarlense 400, P.O. Box 780, São Carlos, São Paulo 13560-960, Brazil
| | - Carlos A. Montanari
- Grupo de Estudos em Química Medicinal de Produtos Naturais−NEQUIMED-PN, Instituto de Química de São Carlos, Universidade de São Paulo, Av. Trabalhador Sancarlense 400, P.O. Box 780, São Carlos, São Paulo 13560-960, Brazil
| | - Pedro I. S. Maia
- Núcleo de Desenvolvimento de Compostos Bioativos (NDCBio), Universidade Federal do Triângulo Mineiro, Uberaba, Minas Gerais 38025-470, Brazil
| | - João S. da Silva
- Departament of Biochemistry and Immunology, School of Medicine, University of São Paulo, Ribeirão Preto, São Paulo 14049-900, Brazil
| | - Sérgio de Albuquerque
- Department of Clinical Toxicological and Bromatological Analysis School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo (USP), Ribeirão Preto, São Paulo 14040-903, Brazil
| | - Zumira A. Carneiro
- Department of Clinical Toxicological and Bromatological Analysis School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo (USP), Ribeirão Preto, São Paulo 14040-903, Brazil
| |
Collapse
|
7
|
Carneiro ZA, Lima JC, Lopes CD, Gaspari APS, de Albuquerque S, Dinelli LR, Veloso-Silva LLW, Paganelli MO, Libardi SH, Oliveira CG, Deflon VM, Oliveira RJ, Borges JC, Maia PIS. Heterobimetallic nickel(II) and palladium(II) complexes derived from S-benzyl-N- (ferrocenyl)methylenedithiocarbazate: Trypanocidal activity and interaction with Trypanosoma cruzi Old Yellow Enzyme (TcOYE). Eur J Med Chem 2019; 180:213-223. [PMID: 31306908 DOI: 10.1016/j.ejmech.2019.07.014] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2019] [Revised: 06/10/2019] [Accepted: 07/04/2019] [Indexed: 10/26/2022]
Abstract
Reactions of Ni(II) and Pd(II) precursors with S-benzyl-N-(ferrocenyl)methylenedithiocarbazate (HFedtc) led to the formation of heterobimetallic complexes of the type [MII(Fedtc)2] (M = Ni and Pd). The characterization of the compounds involved the determination of melting point, FTIR, UV-Vis, 1H NMR, elemental analysis and electrochemical experiments. Furthermore, the crystalline structures of HFedtc and [NiII(Fedtc)2] were determined by single crystal X-ray diffraction. The compounds were evaluated against the intracellular form of Trypanosoma cruzi (Tulahuen Lac-Z strain) and the cytotoxicity assays were assessed using LLC-MK2 cells. The results showed that the coordination of HFedtc to Ni(II) or Pd(II) decreases the in vitro trypanocidal activity while the cytotoxicity against LLC-MK2 cells does not change significantly. [PdII(Fedtc)2] showed the greater potential between the two complexes studied, showing an SI value of 8.9. However, this value is not better than that of the free ligand with an SI of 40, a similar value to that of the standard drug benznidazole (SI = 48). Additionally, molecular docking simulations were performed with Trypanosoma cruzi Old Yellow Enzyme (TcOYE), which predicted that HFedtc binds to the protein, almost parallel to the flavin mononucleotide (FMN) prosthetic group, while the [NiII(Fedtc)2] complex was docked into the enzyme binding site in a significantly different manner. In order to confirm the hypothetical interaction, in vitro experiments of fluorescence quenching and enzymatic activity were performed which indicated that, although HFedtc was not processed by the enzyme, it was able to act as a competitive inhibitor, blocking the hydride transfer from the FMN prosthetic group of the enzyme to the menadione substrate.
Collapse
Affiliation(s)
- Zumira A Carneiro
- Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto - FCFRP-USP, Universidade de São Paulo, Avenida do Café s/n, 14040-903, Ribeirão Preto, SP, Brazil
| | - Jackelinne C Lima
- Núcleo de Desenvolvimento de Compostos Bioativos (NDCBio), Universidade Federal do Triângulo Mineiro, Av. Dr. Randolfo Borges 1400, 38025-440, Uberaba, MG, Brazil
| | - Carla D Lopes
- Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto - FCFRP-USP, Universidade de São Paulo, Avenida do Café s/n, 14040-903, Ribeirão Preto, SP, Brazil
| | - Ana P S Gaspari
- Instituto Federal do Paraná - Campus Paranavaí, Av. José Felipe Tequinha, 1400, 87703-536, Paranavaí, PR, Brazil
| | - Sergio de Albuquerque
- Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto - FCFRP-USP, Universidade de São Paulo, Avenida do Café s/n, 14040-903, Ribeirão Preto, SP, Brazil
| | - Luis R Dinelli
- Faculdade de Ciências Integrada do Pontal, Universidade Federal de Uberlândia, Rua vinte, 1600, 38304-402, Ituiutaba, MG, Brazil
| | - Laudimir L W Veloso-Silva
- São Carlos Institute of Chemistry, University of São Paulo, São Carlos, SP, P.O. Box 780, 13560-970, Brazil
| | - Marcella O Paganelli
- São Carlos Institute of Chemistry, University of São Paulo, São Carlos, SP, P.O. Box 780, 13560-970, Brazil
| | - Silvia H Libardi
- São Carlos Institute of Chemistry, University of São Paulo, São Carlos, SP, P.O. Box 780, 13560-970, Brazil
| | - Carolina G Oliveira
- Instituto de Química, Universidade Federal de Uberlândia, Av. João Naves de Ávila 2121, 38400-902, Uberlândia, MG, Brazil
| | - Victor M Deflon
- São Carlos Institute of Chemistry, University of São Paulo, São Carlos, SP, P.O. Box 780, 13560-970, Brazil
| | - Ronaldo J Oliveira
- Núcleo de Desenvolvimento de Compostos Bioativos (NDCBio), Universidade Federal do Triângulo Mineiro, Av. Dr. Randolfo Borges 1400, 38025-440, Uberaba, MG, Brazil
| | - Júlio C Borges
- São Carlos Institute of Chemistry, University of São Paulo, São Carlos, SP, P.O. Box 780, 13560-970, Brazil
| | - Pedro I S Maia
- Núcleo de Desenvolvimento de Compostos Bioativos (NDCBio), Universidade Federal do Triângulo Mineiro, Av. Dr. Randolfo Borges 1400, 38025-440, Uberaba, MG, Brazil.
| |
Collapse
|
8
|
Paixão DA, Lopes CD, Carneiro ZA, Sousa LM, de Oliveira LP, Lopes NP, Pivatto M, Chaves JDS, de Almeida MV, Ellena J, Moreira MB, Netto AVG, de Oliveira RJ, Guilardi S, de Albuquerque S, Guerra W. In vitro anti-Trypanosoma cruzi activity of ternary copper(II) complexes and in vivo evaluation of the most promising complex. Biomed Pharmacother 2018; 109:157-166. [PMID: 30396072 DOI: 10.1016/j.biopha.2018.10.057] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2018] [Revised: 10/11/2018] [Accepted: 10/11/2018] [Indexed: 12/12/2022] Open
Abstract
In order to improve the previously observed antichagasic activity of Cu(II) complexes containing 2-chlorobenzhydrazide (2-CH), we report herein the synthesis and anti-Trypanosoma cruzi activity of novel copper complexes containing 2-methoxybenzhydrazide (2-MH), 4-methoxybenzhydrazide (4-MH) and three α-diimine ligands, namely, 1,10-phenanthroline (phen), 2,2-bipyridine (bipy) and 4-4'-dimethoxy-2-2'-bipyridine (dmb). Two of these complexes showed higher in vitro anti-Trypanosoma cruzi activity when compared to benznidazole, the main drug used in Chagas disease treatment. One of them, the copper complex with 4-MH and dmb, [Cu(4-MH)(dmb)(ClO4)2], exhibited a higher selectivity index than that recommended for preclinical studies. Considering this observation, complex [Cu(4-MH)(dmb)(ClO4)2] was selected for preliminary in vivo assays, which verified that this compound was able to reduce parasitemia by 64% at the peak of infection. Further investigations were performed on all compounds. The Cu(II) complexes bind to ct-DNA with Kb values in the range of 103-104 M-1, with [Cu(4-MH)(dmb)(ClO4)2] showing the highest Kb value (1.45 × 104 M-1). Molecular docking simulations predicted that [Cu(4-MH)(dmb)(ClO4)2] binds in the minor groove of the double helix of ct-DNA and forms one hydrogen bond.
Collapse
Affiliation(s)
- Drielly A Paixão
- Instituto de Química, Universidade Federal de Uberlândia, Campus Santa Mônica, Uberlândia, MG, Brazil
| | - Carla D Lopes
- Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil
| | - Zumira A Carneiro
- Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil
| | - Luana M Sousa
- Instituto de Química, Universidade Federal de Uberlândia, Campus Santa Mônica, Uberlândia, MG, Brazil
| | - Leticia P de Oliveira
- Instituto de Química, Universidade Federal de Uberlândia, Campus Santa Mônica, Uberlândia, MG, Brazil
| | - Norberto P Lopes
- Núcleo de Pesquisa em Produtos Naturais e Sintéticos (NPPNS), Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil
| | - Marcos Pivatto
- Instituto de Química, Universidade Federal de Uberlândia, Campus Santa Mônica, Uberlândia, MG, Brazil
| | - Joana Darc S Chaves
- Departamento de Química, Universidade Federal de Juiz de Fora, Juiz de Fora-MG, Brazil
| | - Mauro V de Almeida
- Departamento de Química, Universidade Federal de Juiz de Fora, Juiz de Fora-MG, Brazil
| | - Javier Ellena
- Instituto de Física de São Carlos, Universidade de São Paulo, São Carlos, SP, Brazil
| | - Mariete B Moreira
- UNESP - Universidade Estadual Paulista, Instituto de Química, 14800-060, Araraquara-SP, Brazil
| | - Adelino V G Netto
- UNESP - Universidade Estadual Paulista, Instituto de Química, 14800-060, Araraquara-SP, Brazil
| | - Ronaldo J de Oliveira
- Departamento de Física, Instituto de Ciências Exatas, Naturais e Educação, Universidade Federal do Triângulo Mineiro, Uberaba, MG, Brazil
| | - Silvana Guilardi
- Instituto de Química, Universidade Federal de Uberlândia, Campus Santa Mônica, Uberlândia, MG, Brazil
| | - Sérgio de Albuquerque
- Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil
| | - Wendell Guerra
- Instituto de Química, Universidade Federal de Uberlândia, Campus Santa Mônica, Uberlândia, MG, Brazil.
| |
Collapse
|
9
|
Paixão DA, de Oliveira LP, da S. Maia PI, Deflon VM, Carneiro ZA, de Almeida KJ, Lopes NP, Pivatto M, Chaves JDS, de Albuquerque S, de Almeida MV, Guilardi S, Guerra W. Crystal structure of two new polymeric copper(II) complexes active against Trypanosoma cruzi. Journal of Saudi Chemical Society 2018. [DOI: 10.1016/j.jscs.2018.01.002] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
|
10
|
Maia PIDS, Carneiro ZA, Lopes CD, Oliveira CG, Silva JS, de Albuquerque S, Hagenbach A, Gust R, Deflon VM, Abram U. Organometallic gold(iii) complexes with hybrid SNS-donating thiosemicarbazone ligands: cytotoxicity and anti-Trypanosoma cruzi activity. Dalton Trans 2018; 46:2559-2571. [PMID: 28154849 DOI: 10.1039/c6dt04307k] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Stable organogold(iii) compounds of the composition [AuIII(Hdamp)(L1)]Cl are formed from reactions of [AuCl2(damp)] with H2L1 (damp- = dimethylaminomethylphenyl; H2L1 = N'-(diethylcarbamothioyl)benzimidothiosemicarbazides). The cationic complexes can be neutralized by reactions with weak bases under the formation of [AuIII(damp)(L1)] compounds. The structures of the products show interesting features like relatively short AuH contacts between the methylene protons of the Hdamp ligand and the gold(iii) ions. Preliminary biological studies on the uncoordinated compounds H2L1 and their gold complexes indicate considerable cytotoxicity for the [AuIII(Hdamp)(L1)]Cl complexes against MCF-7 cells. The in vitro trypanocidal activity was evaluated against the intracellular form of Trypanosoma cruzi. The organometallic complexes display a remarkable activity, which is dependent on the alkyl substituents of the thiosemicarbazone building blocks of the ligands. One representative of the cationic [AuIII(Hdamp)(L1)]Cl complexes, where H2L1 contains a dimethylthiosemicarbazide building block, shows a trypanocidal activity against the intracellular amastigote form in the same order of magnitude as that of the standard drug benznidazole. Furthermore, no appreciable toxicity to mice spleen cells is observed for this compound resulting in a therapeutic index of about 30, which strongly recommends it as a promising candidate for the development of a future antiparasitic drug.
Collapse
Affiliation(s)
- P I da S Maia
- Departamento de Química, Universidade Federal do Triângulo Mineiro, 38025-440, Uberaba, MG, Brazil.
| | - Z A Carneiro
- Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto - FCFRP-USP, Universidade de São Paulo, Avenida do Café s/n, 14040-903, Ribeirão Preto, SP, Brazil and Department of Biochemistry and Immunology, School of Medicine, University of São Paulo, Av. Bandeirantes 3900, 14040-900, Ribeirão Preto, SP, Brazil
| | - C D Lopes
- Department of Biochemistry and Immunology, School of Medicine, University of São Paulo, Av. Bandeirantes 3900, 14040-900, Ribeirão Preto, SP, Brazil
| | - C G Oliveira
- Instituto de Química de São Carlos, Universidade de São Paulo, Av. Trabalhador São Carlense, 400, 13566-590, São Carlos, SP, Brazil
| | - J S Silva
- Department of Biochemistry and Immunology, School of Medicine, University of São Paulo, Av. Bandeirantes 3900, 14040-900, Ribeirão Preto, SP, Brazil
| | - S de Albuquerque
- Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto - FCFRP-USP, Universidade de São Paulo, Avenida do Café s/n, 14040-903, Ribeirão Preto, SP, Brazil
| | - A Hagenbach
- Freie Universität Berlin, Institute of Chemistry and Biochemistry, Fabeckstr. 34-36, D-14195 Berlin, Germany.
| | - R Gust
- Freie Universität Berlin, Institute of Pharmacy, Königin-Luise-Str. 2+4, 14195 Berlin, Germany
| | - V M Deflon
- Instituto de Química de São Carlos, Universidade de São Paulo, Av. Trabalhador São Carlense, 400, 13566-590, São Carlos, SP, Brazil
| | - U Abram
- Freie Universität Berlin, Institute of Chemistry and Biochemistry, Fabeckstr. 34-36, D-14195 Berlin, Germany.
| |
Collapse
|
11
|
Vaidergorn MM, Carneiro ZA, Lopes CD, de Albuquerque S, Reis FCC, Nikolaou S, Mello JFRE, Genesi GL, Trossini GHG, Ganesan A, Emery FS. β-amino alcohols and their respective 2-phenyl-N-alkyl aziridines as potential DNA minor groove binders. Eur J Med Chem 2018; 157:657-664. [PMID: 30125724 DOI: 10.1016/j.ejmech.2018.07.055] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2018] [Revised: 07/17/2018] [Accepted: 07/23/2018] [Indexed: 02/07/2023]
Abstract
It is known that aziridines and nitrogen mustards exert their biological activities, especially in chemotherapy, via DNA alkylation. The studied scaffold, 2-phenyl-1-aziridine, provides a distinct conformation compared to commonly used aziridines, and therefore, leads to a change in high-strained ring reactivity towards biological nucleophiles, such as DNA. The above series of compounds was tested in three breast cell lines: MCF-10, a healthy cell; MCF-7, a hormone responsive cancer cell; and MDA-MB-231, a triple negative breast cancer cell. Both aziridines and their precursors, β-amino alcohols, showed activity towards these cells, and some of the compounds showed higher selectivity index than cisplatin, the drug used as control. When the type of cell death was investigated, the synthesized compounds demonstrated higher apoptosis and lower necrosis rates than cisplatin, and when the mechanism of action was studied, the compounds were shown to interact with DNA via its minor groove instead of alkylation or intercalation.
Collapse
Affiliation(s)
- Miguel M Vaidergorn
- Departament of Pharmaceutical Sciences, School of Pharmaceutical Sciences of Ribeirão Preto - FCFRP-USP, University of São Paulo, Avenida do Café S/n, Ribeirão Preto, SP, 14040-903, Brazil
| | - Zumira A Carneiro
- Department of Clinical Analyses, Toxicology and Food Science, School of Pharmaceutical Sciences of Ribeirão Preto - FCFRP-USP, University of São Paulo, Brazil
| | - Carla D Lopes
- Department of Clinical Analyses, Toxicology and Food Science, School of Pharmaceutical Sciences of Ribeirão Preto - FCFRP-USP, University of São Paulo, Brazil
| | - Sérgio de Albuquerque
- Department of Clinical Analyses, Toxicology and Food Science, School of Pharmaceutical Sciences of Ribeirão Preto - FCFRP-USP, University of São Paulo, Brazil
| | - Felipe C C Reis
- Departament of Chemistry, Faculty of Philosophy, Sciences and Letters at Ribeirão Preto - FFCLRP-USP, Brazil
| | - Sofia Nikolaou
- Departament of Chemistry, Faculty of Philosophy, Sciences and Letters at Ribeirão Preto - FFCLRP-USP, Brazil
| | - Juliana F R E Mello
- LITEC, Departament of Pharmacy, School of Pharmaceutical Sciences - University of São Paulo, Avenida Prof. Lineu Prestes, 580, Bloco 13 Superior, São Paulo, SP, 05508-000, Brazil
| | - Giovani L Genesi
- LITEC, Departament of Pharmacy, School of Pharmaceutical Sciences - University of São Paulo, Avenida Prof. Lineu Prestes, 580, Bloco 13 Superior, São Paulo, SP, 05508-000, Brazil
| | - Gustavo H G Trossini
- LITEC, Departament of Pharmacy, School of Pharmaceutical Sciences - University of São Paulo, Avenida Prof. Lineu Prestes, 580, Bloco 13 Superior, São Paulo, SP, 05508-000, Brazil
| | - A Ganesan
- School of Pharmacy, University of East Anglia, Norwich, UK
| | - Flavio S Emery
- Departament of Pharmaceutical Sciences, School of Pharmaceutical Sciences of Ribeirão Preto - FCFRP-USP, University of São Paulo, Avenida do Café S/n, Ribeirão Preto, SP, 14040-903, Brazil.
| |
Collapse
|
12
|
Kannen V, Sakita JY, Carneiro ZA, Bader M, Alenina N, Teixeira RR, de Oliveira EC, Brunaldi MO, Gasparotto B, Sartori DC, Fernandes CR, Silva JS, Andrade MV, Silva WA, Uyemura SA, Garcia SB. Mast Cells and Serotonin Synthesis Modulate Chagas Disease in the Colon: Clinical and Experimental Evidence. Dig Dis Sci 2018; 63:1473-1484. [PMID: 29569002 DOI: 10.1007/s10620-018-5015-6] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/05/2016] [Accepted: 03/07/2018] [Indexed: 12/13/2022]
Abstract
BACKGROUND Trypanosoma cruzi (T. cruzi) infects millions of Latin Americans each year and can induce chagasic megacolon. Little is known about how serotonin (5-HT) modulates this condition. Aim We investigated whether 5-HT synthesis alters T. cruzi infection in the colon. MATERIALS AND METHODS Forty-eight paraffin-embedded samples from normal colon and chagasic megacolon were histopathologically analyzed (173/2009). Tryptophan hydroxylase 1 (Tph1) knockout (KO) mice and c-KitW-sh mice underwent T. cruzi infection together with their wild-type counterparts. Also, mice underwent different drug treatments (16.1.1064.60.3). RESULTS In both humans and experimental mouse models, the serotonergic system was activated by T. cruzi infection (p < 0.05). While treating Tph1KO mice with 5-HT did not significantly increase parasitemia in the colon (p > 0.05), rescuing its synthesis promoted trypanosomiasis (p < 0.01). T. cruzi-related 5-HT release (p < 0.05) seemed not only to increase inflammatory signaling, but also to enlarge the pericryptal macrophage and mast cell populations (p < 0.01). Knocking out mast cells reduced trypanosomiasis (p < 0.01), although it did not further alter the neuroendocrine cell number and Tph1 expression (p > 0.05). Further experimentation revealed that pharmacologically inhibiting mast cell activity reduced colonic infection (p < 0.01). A similar finding was achieved when 5-HT synthesis was blocked in c-KitW-sh mice (p > 0.05). However, inhibiting mast cell activity in Tph1KO mice increased colonic trypanosomiasis (p < 0.01). CONCLUSION We show that mast cells may modulate the T. cruzi-related increase of 5-HT synthesis in the intestinal colon.
Collapse
Affiliation(s)
- Vinicius Kannen
- Department of Toxicology, Bromatology, and Clinical Analysis, University of Sao Paulo, Ribeirão Preto, 14040-903, Brazil.
- Department of Pathology, University of Sao Paulo, Ribeirão Preto, Brazil.
| | - Juliana Y Sakita
- Department of Toxicology, Bromatology, and Clinical Analysis, University of Sao Paulo, Ribeirão Preto, 14040-903, Brazil
| | - Zumira A Carneiro
- Department of Toxicology, Bromatology, and Clinical Analysis, University of Sao Paulo, Ribeirão Preto, 14040-903, Brazil
| | - Michael Bader
- Max Delbrück Center for Molecular Medicine, Berlin, Germany
- Charité University Medicine Berlin, Berlin, Germany
- Berlin Institute of Health (BIH), Berlin, Germany
| | - Natalia Alenina
- Max Delbrück Center for Molecular Medicine, Berlin, Germany
- Institute of Translational Biomedicine, St. Petersburg State University, St. Petersburg, Russia
| | - Regina R Teixeira
- Department of Toxicology, Bromatology, and Clinical Analysis, University of Sao Paulo, Ribeirão Preto, 14040-903, Brazil
| | | | | | - Bianca Gasparotto
- Department of Toxicology, Bromatology, and Clinical Analysis, University of Sao Paulo, Ribeirão Preto, 14040-903, Brazil
| | - Daniela C Sartori
- Department of Biochemistry and Immunology, University of São Paulo, Ribeirão Preto, Brazil
| | | | - João S Silva
- Department of Biochemistry and Immunology, University of São Paulo, Ribeirão Preto, Brazil
| | - Marcus V Andrade
- Department of Clinical Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil
| | - Wilson A Silva
- Department of Genetics, University of Sao Paulo, Ribeirão Preto, Brazil
| | - Sergio A Uyemura
- Department of Toxicology, Bromatology, and Clinical Analysis, University of Sao Paulo, Ribeirão Preto, 14040-903, Brazil
| | - Sérgio B Garcia
- Department of Pathology, University of Sao Paulo, Ribeirão Preto, Brazil
| |
Collapse
|
13
|
de Oliveira LP, Carneiro ZA, Ribeiro CM, Lima MF, Paixão DA, Pivatto M, de Souza MVN, Teixeira LR, Lopes CD, de Albuquerque S, Pavan FR, Guerra W. Three new platinum complexes containing fluoroquinolones and DMSO: Cytotoxicity and evaluation against drug-resistant tuberculosis. J Inorg Biochem 2018; 183:77-83. [PMID: 29567518 DOI: 10.1016/j.jinorgbio.2018.03.010] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2018] [Revised: 03/05/2018] [Accepted: 03/14/2018] [Indexed: 11/26/2022]
Abstract
This work describes the synthesis, characterization and biological evaluation of three platinum complexes of the type [Pt(DMSO)(L)Cl]Cl, in which L represents a fluoroquinolone, namely, ciprofloxacin (cpl), ofloxacin (ofl), or sparfloxacin (spf). The new complexes were characterized by elemental analysis, high-resolution mass spectrometry (HRESIMS) and 1H, 13C and 195Pt NMR (nuclear magnetic resonance). The spectral data suggest that the fluoroquinolones act as bidentate ligands coordinated to Pt(II) through the nitrogen atoms of the piperazine ring. Microbiological assays against wild type Mycobacterium tuberculosis (ATCC 27294) showed that all complexes have been very potent, exhibiting antitubercular potency at concentrations <2 μM, although none of the complexes presented higher potency than established anti-TB drugs. As to the resistant strains, the complex with sparfloxacin, [Pt(DMSO)(spf)Cl]Cl exhibited the best potential against most Mycobacterium tuberculosis clinical isolates. The cytotoxicity of these compounds was also evaluated in three breast cell lines: MCF-10 (a healthy cell), MCF-7 (a hormone responsive cancer cell) and MDA-MB-231 (triple negative breast cancer cell). In both tumor cell lines, [Pt(DMSO)(spf)Cl]Cl was more active and more selective than cisplatin. Flow cytometry analysis revealed that [Pt(DMSO)(spf)Cl]Cl induced late apoptotic cell death in MDA-MB-231 cells.
Collapse
Affiliation(s)
- Leticia P de Oliveira
- Instituto de Química, Universidade Federal de Uberlândia, Campus Santa Mônica, Uberlândia, MG, Brazil
| | - Zumira A Carneiro
- Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil
| | - Camila M Ribeiro
- Faculdade de Ciências Farmacêuticas, Universidade Estadual Paulista, Laboratório de Pesquisa em Tuberculose, Campus Araraquara, Araraquara, SP, Brazil
| | - Maurício F Lima
- Instituto de Química, Universidade Federal de Uberlândia, Campus Santa Mônica, Uberlândia, MG, Brazil
| | - Drielly A Paixão
- Instituto de Química, Universidade Federal de Uberlândia, Campus Santa Mônica, Uberlândia, MG, Brazil
| | - Marcos Pivatto
- Instituto de Química, Universidade Federal de Uberlândia, Campus Santa Mônica, Uberlândia, MG, Brazil
| | - Marcus V N de Souza
- Fundação Oswaldo Cruz, Instituto de Tecnologia em Fármacos-FarManguinhos, Manguinhos, Rio de Janeiro, RJ, Brazil
| | - Letícia R Teixeira
- Departamento de Química, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
| | - Carla D Lopes
- Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil
| | - Sérgio de Albuquerque
- Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil
| | - Fernando R Pavan
- Faculdade de Ciências Farmacêuticas, Universidade Estadual Paulista, Laboratório de Pesquisa em Tuberculose, Campus Araraquara, Araraquara, SP, Brazil
| | - Wendell Guerra
- Instituto de Química, Universidade Federal de Uberlândia, Campus Santa Mônica, Uberlândia, MG, Brazil.
| |
Collapse
|
14
|
Gonçalves AC, Carneiro ZA, Oliveira CG, Danuello A, Guerra W, Oliveira RJ, Ferreira FB, Veloso-Silva LL, Batista FA, Borges JC, de Albuquerque S, Deflon VM, Maia PI. Pt II , Pd II and Au III complexes with a thiosemicarbazone derived from diacethylmonooxime: Structural analysis, trypanocidal activity, cytotoxicity and first insight into the antiparasitic mechanism of action. Eur J Med Chem 2017; 141:615-631. [DOI: 10.1016/j.ejmech.2017.10.013] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2017] [Revised: 09/19/2017] [Accepted: 10/07/2017] [Indexed: 11/28/2022]
|
15
|
Rodrigues FP, Carneiro ZA, Mascharak P, Curti C, da Silva RS. Incorporation of a ruthenium nitrosyl complex into liposomes, the nitric oxide released from these liposomes and HepG2 cell death mechanism. Coord Chem Rev 2016. [DOI: 10.1016/j.ccr.2015.03.028] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|
16
|
de Andrade P, Galo OA, Carvalho MR, Lopes CD, Carneiro ZA, Sesti-Costa R, de Melo EB, Silva JS, Carvalho I. 1,2,3-Triazole-based analogue of benznidazole displays remarkable activity against Trypanosoma cruzi. Bioorg Med Chem 2015; 23:6815-26. [PMID: 26476667 DOI: 10.1016/j.bmc.2015.10.008] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2015] [Revised: 09/25/2015] [Accepted: 10/05/2015] [Indexed: 01/29/2023]
Abstract
The current treatment of Chagas disease is based on the use of two drugs, nifurtimox and benznidazole, which present limited efficacy in the chronic stage of the disease and toxic side effects. Although some progress has been made in the development of new drugs to treat this disease, the discovery of novel compounds is urgently required. In this work we report the synthesis and biological evaluation of 1,2,3-triazole-based analogues of benznidazole. A small series of 27 compounds was successfully synthesized via microwave-assisted copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) and ruthenium-catalyzed azide-alkyne cycloaddition (RuAAC) from N-benzyl-2-azidoacetamide (1) and a set of commercial terminal alkynes. Analogues 24 (IC50 40 μM) and 28 (IC50 50 μM) showed comparable activities to benznidazole (IC50 34 μM) against trypomastigote form and analogue 15 (IC50 7 μM) was found to be the most active. Regarding the cytotoxicity assessment of the series, most compounds were not cytotoxic. This work shows that the designed strategy is efficiently capable of generating novel benzindazole analogues and reveals one analogue is more active than benznidazole.
Collapse
Affiliation(s)
- Peterson de Andrade
- School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Av. Café s/n, Ribeirão Preto, SP 14040-930, Brazil
| | - Oswaldo A Galo
- School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Av. Café s/n, Ribeirão Preto, SP 14040-930, Brazil
| | - Marcelo R Carvalho
- School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Av. Café s/n, Ribeirão Preto, SP 14040-930, Brazil
| | - Carla D Lopes
- Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes 3900, Ribeirão Preto, SP 14049-900, Brazil
| | - Zumira A Carneiro
- Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes 3900, Ribeirão Preto, SP 14049-900, Brazil
| | - Renata Sesti-Costa
- Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes 3900, Ribeirão Preto, SP 14049-900, Brazil
| | - Eduardo Borges de Melo
- School of Pharmacy, Western Parana State University, Rua Universitária, 2069, Cascavel, PR 85819-110, Brazil
| | - João S Silva
- Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes 3900, Ribeirão Preto, SP 14049-900, Brazil
| | - Ivone Carvalho
- School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Av. Café s/n, Ribeirão Preto, SP 14040-930, Brazil.
| |
Collapse
|
17
|
Campo VL, Ivanova IM, Carvalho I, Lopes CD, Carneiro ZA, Saalbach G, Schenkman S, da Silva JS, Nepogodiev SA, Field RA. Click chemistry oligomerisation of azido-alkyne-functionalised galactose accesses triazole-linked linear oligomers and macrocycles that inhibit Trypanosoma cruzi macrophage invasion. Tetrahedron 2015; 71:7344-7353. [PMID: 26435551 PMCID: PMC4542550 DOI: 10.1016/j.tet.2015.04.085] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Reaction of 2-(2-(2-azidoethoxy)ethoxy)ethyl 6-O-(prop-2-ynyl)-β-d-galactopyranoside (7) under CuAAC conditions gives rise to mixed cyclic and linear triazole-linked oligomers, with individual compounds up to d.p. 5 isolable, along with mixed larger oligomers. The linear compounds resolve en bloc from the cyclic materials by RP HPLC, but are separable by gel permeation chromatography. The triazole-linked oligomers—pseudo-galactooligomers—were demonstrated to be acceptor substrates for the multi-copy cell surface trans-sialidase of the human parasite Trypanosoma cruzi. In addition, these multivalent TcTS ligands were able to block macrophage invasion by T. cruzi.
Collapse
Affiliation(s)
- Vanessa L Campo
- Faculdade de Ciências Farmacêuticas de Ribeirão Preto, USP, Av. Café S/N, CEP 14040-903, Ribeirão Preto, SP, Brazil
| | - Irina M Ivanova
- Department of Biological Chemistry, John Innes Centre, Norwich Research Park, Norwich NR4 7UH, UK
| | - Ivone Carvalho
- Faculdade de Ciências Farmacêuticas de Ribeirão Preto, USP, Av. Café S/N, CEP 14040-903, Ribeirão Preto, SP, Brazil
| | - Carla D Lopes
- Faculdade de Medicina de Ribeirão Preto, Department of Parasitology Microbiology and Immunology, USP, Av. Bandeirantes 3900, CEP 14049-900, Ribeirão Preto, SP, Brazil
| | - Zumira A Carneiro
- Faculdade de Medicina de Ribeirão Preto, Department of Parasitology Microbiology and Immunology, USP, Av. Bandeirantes 3900, CEP 14049-900, Ribeirão Preto, SP, Brazil
| | - Gerhard Saalbach
- Department of Biological Chemistry, John Innes Centre, Norwich Research Park, Norwich NR4 7UH, UK
| | - Sergio Schenkman
- Department of Microbiology, Immunology and Parasitology, Universidade Federal de São Paulo, Rua Botucatu 862 8, Andar 04023-062, São Paulo, SP, Brazil
| | - João Santana da Silva
- Faculdade de Medicina de Ribeirão Preto, Department of Parasitology Microbiology and Immunology, USP, Av. Bandeirantes 3900, CEP 14049-900, Ribeirão Preto, SP, Brazil
| | - Sergey A Nepogodiev
- Department of Biological Chemistry, John Innes Centre, Norwich Research Park, Norwich NR4 7UH, UK
| | - Robert A Field
- Department of Biological Chemistry, John Innes Centre, Norwich Research Park, Norwich NR4 7UH, UK
| |
Collapse
|
18
|
Cândido MCL, Oliveira AM, Silva FON, Holanda AKM, Pereira WG, Sousa EHS, Carneiro ZA, Silva RS, Lopes LGF. Photochemical and Electrochemical Study of the Release of Nitric Oxide from [Ru(bpy) 2L(NO)](PF 6) nComplexes (L = Imidazole, 1-Methylimidazole, Sulfite and Thiourea), Toward the Development of Therapeutic Photodynamic Agents. J BRAZIL CHEM SOC 2015. [DOI: 10.5935/0103-5053.20150159] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
19
|
Sesti-Costa R, Carneiro ZA, Silva MC, Santos M, Silva GK, Milanezi C, da Silva RS, Silva JS. Ruthenium complex with benznidazole and nitric oxide as a new candidate for the treatment of chagas disease. PLoS Negl Trop Dis 2014; 8:e3207. [PMID: 25275456 PMCID: PMC4183476 DOI: 10.1371/journal.pntd.0003207] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2014] [Accepted: 08/22/2014] [Indexed: 01/01/2023] Open
Abstract
BACKGROUND Chagas disease remains a serious medical and social problem in Latin America and is an emerging concern in nonendemic countries as a result of population movement, transfusion of infected blood or organs and congenital transmission. The current treatment of infected patients is unsatisfactory due to strain-specific drug resistance and the side effects of the current medications. For this reason, the discovery of safer and more effective chemotherapy is mandatory for the successful treatment and future eradication of Chagas disease. METHODS AND FINDINGS We investigated the effect of a ruthenium complex with benznidazole and nitric oxide (RuBzNO2) against Trypanosoma cruzi both in vitro and in vivo. Our results demonstrated that RuBzNO2 was more effective than the same concentrations of benznidazole (Bz) in eliminating both the extracellular trypomastigote and the intracellular amastigote forms of the parasite, with no cytotoxic effect in mouse cells. In vivo treatment with the compound improved the survival of infected mice, inhibiting heart damage more efficiently than Bz alone. Accordingly, tissue inflammation and parasitism was significantly diminished after treatment with RuBzNO2 in a more effective manner than that with the same concentrations of Bz. CONCLUSIONS The complexation of Bz with ruthenium and nitric oxide (RuBzNO2) increases its effectiveness against T. cruzi and enables treatment with lower concentrations of the compound, which may reduce the side effects of Bz. Our findings provide a new potential candidate for the treatment of Chagas disease.
Collapse
Affiliation(s)
- Renata Sesti-Costa
- Department of Biochemistry and Immunology, Medical School of Ribeirão Preto, São Paulo, Brazil
| | - Zumira A. Carneiro
- School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil
| | - Maria C. Silva
- Department of Biochemistry and Immunology, Medical School of Ribeirão Preto, São Paulo, Brazil
| | - Maíta Santos
- School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil
| | - Grace K. Silva
- Department of Biochemistry and Immunology, Medical School of Ribeirão Preto, São Paulo, Brazil
| | - Cristiane Milanezi
- Department of Biochemistry and Immunology, Medical School of Ribeirão Preto, São Paulo, Brazil
| | - Roberto S. da Silva
- School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil
| | - João S. Silva
- Department of Biochemistry and Immunology, Medical School of Ribeirão Preto, São Paulo, Brazil
- * E-mail:
| |
Collapse
|
20
|
Carneiro ZA, da S. Maia PI, Sesti-Costa R, Lopes CD, Pereira TA, Milanezi CM, da Silva MAP, Lopez RFV, Silva JS, Deflon VM. In vitro and in vivo trypanocidal activity of H2bdtc-loaded solid lipid nanoparticles. PLoS Negl Trop Dis 2014; 8:e2847. [PMID: 24810753 PMCID: PMC4014426 DOI: 10.1371/journal.pntd.0002847] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2013] [Accepted: 03/25/2014] [Indexed: 01/24/2023] Open
Abstract
The parasite Trypanosoma cruzi causes Chagas disease, which remains a serious public health concern and continues to victimize thousands of people, primarily in the poorest regions of Latin America. In the search for new therapeutic drugs against T. cruzi, here we have evaluated both the in vitro and the in vivo activity of 5-hydroxy-3-methyl-5-phenyl-pyrazoline-1-(S-benzyl dithiocarbazate) (H2bdtc) as a free compound or encapsulated into solid lipid nanoparticles (SLN); we compared the results with those achieved by using the currently employed drug, benznidazole. H2bdtc encapsulated into solid lipid nanoparticles (a) effectively reduced parasitemia in mice at concentrations 100 times lower than that normally employed for benznidazole (clinically applied at a concentration of 400 µmol kg(-1) day(-1)); (b) diminished inflammation and lesions of the liver and heart; and (c) resulted in 100% survival of mice infected with T. cruzi. Therefore, H2bdtc is a potent trypanocidal agent.
Collapse
Affiliation(s)
- Zumira A. Carneiro
- Faculdade de Ciências Farmacêuticas de Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil
| | - Pedro I. da S. Maia
- Instituto de Química de São Carlos, University of São Paulo, São Carlos, São Paulo, Brazil
| | - Renata Sesti-Costa
- Departamento de Bioquímica e Imunologia, School of Medicine, University of São Paulo, Ribeirão Preto, São Paulo, Brazil
| | - Carla D. Lopes
- Departamento de Bioquímica e Imunologia, School of Medicine, University of São Paulo, Ribeirão Preto, São Paulo, Brazil
| | - Tatiana A. Pereira
- Faculdade de Ciências Farmacêuticas de Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil
| | - Cristiane M. Milanezi
- Departamento de Bioquímica e Imunologia, School of Medicine, University of São Paulo, Ribeirão Preto, São Paulo, Brazil
| | - Marcelo A. Pereira. da Silva
- Instituto de Física de São Carlos, University of São Paulo, São Carlos, São Paulo, Brazil
- Centro Universitário Central Paulista - UNICEP, São Carlos, São Paulo, Brazil
| | - Renata F. V. Lopez
- Faculdade de Ciências Farmacêuticas de Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil
| | - João S. Silva
- Departamento de Bioquímica e Imunologia, School of Medicine, University of São Paulo, Ribeirão Preto, São Paulo, Brazil
| | - Victor M. Deflon
- Instituto de Química de São Carlos, University of São Paulo, São Carlos, São Paulo, Brazil
| |
Collapse
|
21
|
Junqueira GG, Carvalho MR, Andrade PD, Lopes CD, Carneiro ZA, Sesti-Costa R, Silva JS, Carvalho I. Synthesis andin vitroEvaluation of Novel Galactosyl-triazolo-benzenesulfonamides AgainstTrypanosoma cruzi. J BRAZIL CHEM SOC 2014. [DOI: 10.5935/0103-5053.20140158] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
22
|
Wiggers HJ, Rocha JR, Fernandes WB, Sesti-Costa R, Carneiro ZA, Cheleski J, da Silva ABF, Juliano L, Cezari MHS, Silva JS, McKerrow JH, Montanari CA. Non-peptidic cruzain inhibitors with trypanocidal activity discovered by virtual screening and in vitro assay. PLoS Negl Trop Dis 2013; 7:e2370. [PMID: 23991231 PMCID: PMC3750009 DOI: 10.1371/journal.pntd.0002370] [Citation(s) in RCA: 56] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2012] [Accepted: 07/04/2013] [Indexed: 11/19/2022] Open
Abstract
A multi-step cascade strategy using integrated ligand- and target-based virtual screening methods was developed to select a small number of compounds from the ZINC database to be evaluated for trypanocidal activity. Winnowing the database to 23 selected compounds, 12 non-covalent binding cruzain inhibitors with affinity values (Ki) in the low micromolar range (3–60 µM) acting through a competitive inhibition mechanism were identified. This mechanism has been confirmed by determining the binding mode of the cruzain inhibitor Nequimed176 through X-ray crystallographic studies. Cruzain, a validated therapeutic target for new chemotherapy for Chagas disease, also shares high similarity with the mammalian homolog cathepsin L. Because increased activity of cathepsin L is related to invasive properties and has been linked to metastatic cancer cells, cruzain inhibitors from the same library were assayed against it. Affinity values were in a similar range (4–80 µM), yielding poor selectivity towards cruzain but raising the possibility of investigating such inhibitors for their effect on cell proliferation. In order to select the most promising enzyme inhibitors retaining trypanocidal activity for structure-activity relationship (SAR) studies, the most potent cruzain inhibitors were assayed against T. cruzi-infected cells. Two compounds were found to have trypanocidal activity. Using compound Nequimed42 as precursor, an SAR was established in which the 2-acetamidothiophene-3-carboxamide group was identified as essential for enzyme and parasite inhibition activities. The IC50 value for compound Nequimed42 acting against the trypomastigote form of the Tulahuen lacZ strain was found to be 10.6±0.1 µM, tenfold lower than that obtained for benznidazole, which was taken as positive control. In addition, by employing the strategy of molecular simplification, a smaller compound derived from Nequimed42 with a ligand efficiency (LE) of 0.33 kcal mol−1 atom−1 (compound Nequimed176) is highlighted as a novel non-peptidic, non-covalent cruzain inhibitor as a trypanocidal agent candidate for optimization. Chagas disease (American trypanosomiasis) is a parasitic infection that kills millions of mostly poverty-stricken people in Latin America. In recent years it has also spread to nonendemic countries – the United States, Canada, Europe, Australia and Japan – as a result of immigration. The only available drugs for its treatment were introduced more than forty years ago, have low efficacy, and cause various severe side effects. This dire public health situation has prompted us to search for new small molecules to act as drug candidates to treat Chagas disease. The T. cruzi enzyme cruzain, a key biological catalyst used by the protozoan to digest host proteins, is a validated drug target for Chagas disease. By combining in silico molecular design, X-ray crystallography and biological screening, we found a new class of non-covalent small molecules that inhibit cruzain in low micromolar concentrations.
Collapse
Affiliation(s)
- Helton J. Wiggers
- Departamento de Química, Universidade Federal de São Carlos, São Carlos, São Paulo, Brazil
- Grupo de Química Medicinal do IQSC/USP, Instituto de Química de São Carlos, Universidade de São Paulo, São Carlos, São Paulo, Brazil
| | - Josmar R. Rocha
- Grupo de Química Medicinal do IQSC/USP, Instituto de Química de São Carlos, Universidade de São Paulo, São Carlos, São Paulo, Brazil
| | - William B. Fernandes
- Grupo de Química Medicinal do IQSC/USP, Instituto de Química de São Carlos, Universidade de São Paulo, São Carlos, São Paulo, Brazil
- University of California San Francisco, Center for Discovery and Innovation in Parasitic Diseases (CDIPD), Department of Pathology, San Francisco, California, United States of America
| | - Renata Sesti-Costa
- Departamento de Bioquímica e Imunologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brazil
| | - Zumira A. Carneiro
- Departamento de Bioquímica e Imunologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brazil
| | - Juliana Cheleski
- Grupo de Química Medicinal do IQSC/USP, Instituto de Química de São Carlos, Universidade de São Paulo, São Carlos, São Paulo, Brazil
| | - Albérico B. F. da Silva
- Grupo de Química Medicinal do IQSC/USP, Instituto de Química de São Carlos, Universidade de São Paulo, São Carlos, São Paulo, Brazil
| | - Luiz Juliano
- Departamento de Biofísica, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil
| | - Maria H. S. Cezari
- Departamento de Biofísica, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil
| | - João S. Silva
- Departamento de Bioquímica e Imunologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brazil
| | - James H. McKerrow
- University of California San Francisco, Center for Discovery and Innovation in Parasitic Diseases (CDIPD), Department of Pathology, San Francisco, California, United States of America
- * E-mail: (JHM); (CAM)
| | - Carlos A. Montanari
- Departamento de Química, Universidade Federal de São Carlos, São Carlos, São Paulo, Brazil
- Grupo de Química Medicinal do IQSC/USP, Instituto de Química de São Carlos, Universidade de São Paulo, São Carlos, São Paulo, Brazil
- * E-mail: (JHM); (CAM)
| |
Collapse
|
23
|
Martins-Teixeira MB, Campo VL, Biondo M, Sesti-Costa R, Carneiro ZA, Silva JS, Carvalho I. α-Selective glycosylation affords mucin-related GalNAc amino acids and diketopiperazines active on Trypanosoma cruzi. Bioorg Med Chem 2013; 21:1978-87. [DOI: 10.1016/j.bmc.2013.01.027] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2012] [Revised: 01/03/2013] [Accepted: 01/11/2013] [Indexed: 11/28/2022]
|